Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$22.83M+128.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joel D. Becker
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 220
- Beta
- 1.95
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.70
Financials
Revenue
$22.83M+128.8%Net Income
$-6.20MEBITDA
$-4.56MFree Cash Flow
$-4.03MEPS (diluted)
$-0.18Shares Outstanding (diluted)
34.10M+207.2%Operating Expenses
$24.05MCash & Debt
$51.70MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $99.99M | $-21.46M | $-0.66 |
| 2024 | $79.91M | $-27.14M | $-0.93 |
| 2023 | $65.42M | $-32.96M | $-1.27 |
| 2022 | $45.52M | $-47.08M | $-1.91 |
| 2021 | $45.18M | $-36.08M | $-2.17 |
| 2020 | $41.14M | $-24.28M | $-2.17 |
| 2019 | $36.97M | $-29.97M | $-2.70 |
Valuation
NPCEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-41.18%Social Signal Score
Mentions (10)
- Newszacks.com·25d ago·Neutral
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·31d ago·Positive
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
View source ↗ - Newsbusinesswire.com·34d ago·Neutral
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investor…
View source ↗ - Newszacks.com·49d ago·Neutral
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.
View source ↗ - Newszacks.com·49d ago·Neutral
Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated? NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.
View source ↗ - Newszacks.com·49d ago·Positive
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity? NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·54d ago·Neutral
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.
View source ↗ - Newsmarketbeat.com·55d ago·Negative
NeuroPace Q2 Earnings Call Highlights NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food and Drug Administration regarding its application to expand the RNS System's indication into idiopathic generalized epilepsy, or IGE.
View source ↗ - Newszacks.com·55d ago·Negative
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.11 per share
Typical surprise +19.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.18 vs $-0.22beat
- Tue, May 12$-0.20 vs $-0.19miss
- Tue, Mar 3$-0.08 vs $-0.14beat
- Tue, Nov 4$-0.11 vs $-0.20beat
- Tue, Aug 12$-0.26 vs $-0.24miss
- Tue, May 13$-0.21 vs $-0.26beat
Estimates and results for NPCE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NPCE officers and directors.
- Bought
- —
- Sold
- $399k
0 trades
1 trade
- Morrell Marthasold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NPCE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.